Should You Buy Pfizer Stock After the Fantastic COVID-19 Pill News? | The Motley Fool

Pretty much everyone thought that Merck and its partner, Ridgeback Biotherapeutics, set a really high bar with the late-stage results for their COVID-19 pill, molnupiravir.

The company reported last Friday that Paxlovid reduced the risk of hospitalization by 89% compared with a placebo in COVID-19 patients who were treated within three days of symptom onset.

If Paxlovid wins authorization , the pill could be prescribed to adults who are diagnosed with COVID-19.

The number of COVID-19 cases could decline in the future thanks in large part to increased vaccination rates.

The candidate didn’t meet the primary endpoint in a phase 2 study, but Atea and Roche plan to move forward with a phase 3 study with potential protocol modifications.

With the potential for Paxlovid to be a megablockbuster as well, Pfizer’s cash stockpile should continue to grow by leaps and bounds.

…Read the full story